Guiyang Xintian Pharmaceutical Co Ltd (SHE:002873) — Market Cap & Net Worth
Market Cap & Net Worth: Guiyang Xintian Pharmaceutical Co Ltd (002873)
Guiyang Xintian Pharmaceutical Co Ltd (SHE:002873) has a market capitalization of $360.77 Million (CN¥2.47 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #14176 globally and #4460 in its home market, demonstrating a 6.09% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guiyang Xintian Pharmaceutical Co Ltd's stock price CN¥10.10 by its total outstanding shares 244103806 (244.10 Million). Analyse 002873 operating cash flow to see how efficiently the company converts income to cash.
Guiyang Xintian Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Guiyang Xintian Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $436.01 Million to $360.77 Million (3.18% CAGR).
Guiyang Xintian Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guiyang Xintian Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.39x
Guiyang Xintian Pharmaceutical Co Ltd's market cap is 0.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.47x
Guiyang Xintian Pharmaceutical Co Ltd's market cap is 6.47 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $436.01 Million | $681.71 Million | $66.12 Million | 0.64x | 6.59x |
| 2018 | $285.18 Million | $694.26 Million | $70.98 Million | 0.41x | 4.02x |
| 2019 | $297.01 Million | $773.34 Million | $71.42 Million | 0.38x | 4.16x |
| 2020 | $287.87 Million | $750.95 Million | $72.55 Million | 0.38x | 3.97x |
| 2021 | $504.10 Million | $969.84 Million | $99.48 Million | 0.52x | 5.07x |
| 2022 | $509.43 Million | $1.09 Billion | $111.52 Million | 0.47x | 4.57x |
| 2023 | $441.29 Million | $953.98 Million | $80.87 Million | 0.46x | 5.46x |
| 2024 | $338.27 Million | $857.55 Million | $52.32 Million | 0.39x | 6.47x |
Competitor Companies of 002873 by Market Capitalization
Companies near Guiyang Xintian Pharmaceutical Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Guiyang Xintian Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Guiyang Xintian Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Guiyang Xintian Pharmaceutical Co Ltd's market cap moved from $436.01 Million to $ 360.77 Million, with a yearly change of 3.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥360.77 Million | +1.81% |
| 2025 | CN¥354.34 Million | +4.75% |
| 2024 | CN¥338.27 Million | -23.34% |
| 2023 | CN¥441.29 Million | -13.38% |
| 2022 | CN¥509.43 Million | +1.06% |
| 2021 | CN¥504.10 Million | +75.11% |
| 2020 | CN¥287.87 Million | -3.08% |
| 2019 | CN¥297.01 Million | +4.15% |
| 2018 | CN¥285.18 Million | -34.59% |
| 2017 | CN¥436.01 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Guiyang Xintian Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $360.77 Million USD |
| MoneyControl | $360.77 Million USD |
| MarketWatch | $360.77 Million USD |
| marketcap.company | $360.77 Million USD |
| Reuters | $360.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guiyang Xintian Pharmaceutical Co Ltd
Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of new Chinese patent medicines in China. The company offers products in various dosage forms, including hard capsules, mixtures, granules, gels, tablets, syrups, wine preparation, dews preparations, and two Chinese medicine preparation production lines. Its products are used for the treatment of… Read more